Brief: Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin
18/03/2024 20:09
March 19 (Reuters) - Inventiva SA IVAA.PA :
* INVENTIVA ANNOUNCES POSITIVE RESULTS FROM THE PHASE II,
LEGEND,
PROOF-OF-CONCEPT STUDY COMBINING LANIFIBRANOR WITH EMPAGLIFLOZIN
IN PATIENTS WITH MASH/NASH AND T2D
Source text for Eikon: ID:nGNXb1kb9k
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030